Compare
Aethlon Medical Inc vs GeoVax Labs, Inc. vs OS Therapies Inc vs Ernexa Therapeutics Inc.
| Latest fiscal year | Aethlon Medical Inc AEMD | GeoVax Labs, Inc. GOVX | OS Therapies Inc OSTX | Ernexa Therapeutics Inc. ERNA |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $2.49M | n/a | n/a |
| Revenue growth (YoY) | n/a | -37.1% | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -869.3% | n/a | n/a |
| Net margin | n/a | -862.3% | n/a | n/a |
| Net income | -$7.15M | -$21.46M | -$28.75M | -$14.08M |
| EPS (Diluted) | -$10.61 | n/a | -$0.98 | -$2.24 |
| Operating cash flow | -$7.00M | -$21.47M | -$14.24M | -$7.02M |
| Free cash flow | -$7.00M | -$21.50M | -$14.70M | -$7.05M |
| Cash & equivalents | $5.03M | $3.09M | n/a | n/a |
| Total assets | $6.33M | $6.34M | $6.84M | $5.83M |
| Total liabilities | $1.45M | $2.52M | $11.86M | $3.43M |
| Shareholders' equity | $4.89M | $3.83M | -$6.10M | $2.40M |
| Return on year-end equity | -146.4% | -561.2% | n/a | -586.6% |
| Shares outstanding | 1.57M | 1.73M | 37.11M | 7.85M |
Revenue, most recent five fiscal years
| Fiscal year | Aethlon Medical Inc | GeoVax Labs, Inc. | OS Therapies Inc | Ernexa Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2024-03-31 | $2.49M Ended 2025-12-31 | n/a | $582.0K Ended 2024-12-31 |
| 1 year earlier | $574.2K Ended 2023-03-31 | $3.95M Ended 2024-12-31 | n/a | $68.0K Ended 2023-12-31 |
| 2 years earlier | $294.2K Ended 2022-03-31 | $0 Ended 2023-12-31 | n/a | $0 Ended 2022-12-31 |
| 3 years earlier | $659.1K Ended 2021-03-31 | $81.5K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $650.2K Ended 2020-03-31 | $385.5K Ended 2021-12-31 | n/a | $5.80M Ended 2020-12-31 |